CAS 870262-90-1

Letaxaban

Description:

Letaxaban, identified by its CAS number 870262-90-1, is an investigational anticoagulant that belongs to the class of direct factor Xa inhibitors. It is designed to prevent thrombus formation by selectively inhibiting factor Xa, an essential enzyme in the coagulation cascade. Letaxaban exhibits high oral bioavailability and a predictable pharmacokinetic profile, which allows for fixed dosing without the need for routine monitoring of anticoagulation levels. The substance is characterized by its relatively short half-life, which may necessitate regular dosing to maintain therapeutic effects. In preclinical and clinical studies, Letaxaban has demonstrated efficacy in reducing the risk of venous thromboembolism and other thrombotic events. Its safety profile is still under investigation, but like other anticoagulants, it may carry risks of bleeding. Overall, Letaxaban represents a promising option in the field of anticoagulation therapy, with ongoing research aimed at fully elucidating its therapeutic potential and safety.

Letaxaban

CAS: 870262-90-1

Letaxaban (TAK-442) is a small molecule Xa factor inhibitor that can be used to study polar coronary syndromes and thrombotic blockages.

Formula: C₂₂H₂₆ClN₃O₅S

Purity: 99.13% - 99.87%

Color and Shape: Solid

Molecular weight: 479.98

Ref: TM-T68092

Letaxaban

CAS: 870262-90-1

Letaxaban

Purity: ≥98%

Molecular weight: 479.98g/mol

Ref: 54-BUP03872

Letaxaban

CAS: 870262-90-1

Letaxaban is an anticoagulant drug that inhibits the enzyme thrombin by covalent binding. It is used in the treatment of deep vein thrombosis, pulmonary embolism and atrial fibrillation. Letaxaban also has a specific antidote for use in cases of overdose or suspected overdose. Letaxaban has been shown to have a synergistic effect with aspirin and clopidogrel, as well as with natural compounds such as coumarin derivatives and chemoattractant protein. The low-dose group showed improved pharmacokinetic properties compared with the high-dose group, which may be due to increased bioavailability and reduced degradation by cytochrome P450 enzymes.

Formula: C₂₂H₂₆ClN₃O₅S

Purity: Min. 95%

Molecular weight: 479.98 g/mol

Ref: 3D-FL24871